3 New Members on the CATALIS’ Board of Directors | CATALIS is pleased to announce the appointments of Alain Couture, Natalie Verreault and Patrick Montpetit to the Board of Directors as board members. | The Board of Directors Welcomes Alain Couture | "It is with great pleasure that I join the CATALIS Board of Directors. I am eager to contribute to the organization’s initiatives and collaborate to support the mission of advancing and accelerating clinical research. My goal is to promote the integration of health innovations and attract more research investments to Quebec, all for the benefit of patients." - Alain Couture, Senior Head, Government Affairs and Strategic Partnerships for Quebec, GSK | | Alain Couture holds a Bachelor's degree in Business Administration from Laval University. He is currently Senior Head of Government Affairs and Strategic Partnerships for Quebec at GSK. Over his 30-year tenure at GSK, Mr. Couture has developed a deep expertise in government affairs management, market access, sales, and the development of strategic relationships with external clients and key stakeholders in the healthcare sector. Alain has been a member of the steering committee of Innovative Medicines Canada (IMC) for over 10 years. He represents GSK in organizations such as Montreal InVivo and Québec International, as well as other major life sciences bodies. | The Board of Directors Welcomes Natalie Verreault | "It is a privilege to join CATALIS Quebec’s Board of Directors, a leading organization dedicated to accelerating clinical research. Placing patients’ needs at the heart of priorities is a crucial responsibility. I am eager to collaborate with this board of leaders to support the development of initiatives that concretely improve access to innovative treatments, thereby meeting the expectations of Quebec patients. Together, we are working to transform their care experience, advance science, and bring hope." - Natalie Verreault, Senior Manager, Health System and Government Affairs, Roche Canada | | Natalie Verreault, Senior Manager of Health System and Government Affairs at Roche Canada, has over 25 years of experience in the pharmaceutical industry. A graduate of Laval University's business administration program, Natalie is also a Certified Market Access Professional (CAHR). She has developed deep expertise in management, sales, strategic partnership development, and government affairs. She is actively involved in Innovative Medicines Canada (IMC) and several sectorial working groups. | The Board of Directors Welcomes Patrick Montpetit | "I am honored to join the Board of Directors of CATALIS Quebec and to support its mission. Optimizing the clinical research environment by putting patients at the center of its priorities positions Quebec as a major player in the international biotechnology industry. I am truly moved to finally be able to contribute my expertise of the last 30 years to the benefit of our patients." - Patrick Montpetit CPA, Executive Chairman, Biodextris | | As a partner and Chief Financial Officer of private and public companies for 28 years, Patrick Montpetit has a proven track record of leadership focused on creating value and developing growth strategies to maximize shareholder value from an exit perspective. As a Canadian CPA, he brings extensive international financial management experience, having worked in North America, Europe, LATAM, and Asia. | Thank You to the Outgoing Members of the Board of Directors The members of the Board of Directors would like to express their gratitude to the outgoing members, Jefferson Tea and Patrice Roy, for their invaluable contribution. Having served on the Board since 2019 and 2023 respectively, both have demonstrated an outstanding commitment to the mission of CATALIS. | 6 New Members Join the CATALIS Network | 4 New HSSIs Join the CATALIS Network | CATALIS Quebec is proud to announce that the reach of its services now extends to 27 institutions across the province, with the integration of four (4) new health and social services institutions (HSSIs) into its Network of partners: The CISSS de la Côte-Nord, the CISSS Gaspésie, the CISSS de la Montérégie-Est, and the CISSS de la Montérégie-Ouest. | The Johnson & Johnson Pharmaceutical Company Joins
the CATALIS Network | CATALIS is pleased to welcome the Johnson & Johnson Innovative Medicine Canada pharmaceutical company to its Network of partners. Johnson & Johnson focuses its efforts on complex diseases and develops the medicines of tomorrow in various fields, such as oncology, immunology, neuroscience, and rare diseases. Johnson & Johnson joins the industry partners already engaged with our Network: Abbvie, Alexion, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences Canada Inc., GSK, Lilly Canada, Merck, Novartis, Novo Nordisk Canada Inc., Pfizer, Roche, Sanofi, Takeda, and Vertex. | “Johnson & Johnson is proud to collaborate with the CATALIS Network to drive clinical trials forward in the province. This is a win for patients, who will gain access to leading edge research; for clinicians and other researchers, who are helping accelerate the pace of discovery; and for the health and life sciences sectors, which will see growth of the discovery industry in support of the rapid commercialization of potentially life-changing innovations.” - Ebele Ola, Vice President, Medical Affairs, Johnson & Johnson Innovative Medicine. Canada | | The Canadian Hemophilia Society - Quebec Chapter Joins
the CATALIS Network | CATALIS Quebec is pleased to welcome the Canadian Hemophilia Society - Quebec Chapter to its Network of partners! The Canadian Hemophilia Society - Quebec Chapter is committed to improving the health and quality of life of people with inherited blood-clotting disorders by ensuring access to the best available treatments and well-equipped care centers. Alongside more than thirty patient organizations and patient partners representing the voices of patients and caregivers within our Network, the CHSQ strengthens our shared commitment to accelerating medical innovation for the population of Quebec. | “Thanks to our partnership with CATALIS, we will be able to achieve our goal of providing patients with tools to learn about clinical trials and discuss them with their hematologist. We also believe that the CATALIS Network provides a collaborative space to discuss innovative treatments using a learning organization approach. We are proud and excited to join the CATALIS Network, a key partner in our mission to improve the quality of life for people with coagulation disorders.” - Aline Ostrowski, Executive Director of the Canadian Hemophilia Society - Quebec Chapter | | CATALIS would like to thank all members of its Network for their expertise and commitment to accelerating the development of innovative treatments. Together, we continue to improve the clinical research ecosystem for the well-being of patients in Quebec. | The MUHC Authorizes an AstraZeneca Study on Metastatic Lung Cancer in 8 weeks and Recruits the First Patient in the World | With the support of the FAST TRACK Evaluation Service coordinated by CATALIS Quebec, the McGill University Health Centre (MUHC) was able to obtain authorization in 8 weeks for the ARTEMIDE-Lung03 study conducted by AstraZeneca, and was able to activate the site in 10.8 weeks, making it the second site activated in the world. The team, led by the MUHC’s Dr. Scott Owen, also recruited the first patient worldwide for this phase III study on metastatic non-small cell lung cancer (NSCLC). | | | "AstraZeneca is proud to partner with CATALIS to expand and accelerate clinical research in Quebec. By using the CATALIS FAST TRACK Evaluation Service, we were able to launch the ARTEMIDE-Lung03 study in non-small cell lung cancer (NSCLC) in just 10.8 weeks. In collaboration with the McGill University Health Centre, we also successfully randomized the first global patient for this expansive phase III study. This is a great collaboration among AstraZeneca, CATALIS, researchers, and healthcare organizations and emphasizes our commitment to advancing rapid access to innovative treatments and improving patient outcomes." - Gaby Bourbara, President, AstraZeneca Canada | | | "Lung cancer continues to be the number one cancer killer worldwide and in Canada, and most patients are diagnosed with advanced, metastatic disease. Although there have been great strides in therapies that help to improve survival and quality of life for patients with this disease, much more still needs to be done. ARTEMIDE-lung 03 and ARTEMID-lung 02 areis a phase 3 trials that aim to demonstrate improved survival by combining two ways to prevent cancer from evading our body’s immune system (anti-PDL1 and anti-TIGIT activity). The MUHC is proud to be able to offer theseis studiesy to patients and to boast the second patient worldwide recruited to ARTEMIDE-lung 03." – Scott Owen MD, Investigator, RI-MUHC, Assistant Professor, Gerald Bronfman Department of Oncology, McGill University | | Amgen Canada Obtains Authorization in 8 Weeks for Its Study on Lung Cancer at the MUHC, Making It the First Site Activated in Canada | Amgen Canada used CATALIS Quebec’s FAST TRACK Evaluation Service for its 20230153 Phase II study on non-small cell lung cancer (NSCLC). Through this initiative, the research team, led by Dr. Benjamin Shieh at the McGill University Health Centre (MUHC), was able to obtain a speedy launch, with an authorization time of 8 weeks and an activation time of 9.8 weeks, making the MUHC the first site activated in Canada. This breakthrough accelerates patient access to promising new treatment options. | | | "Our first experience with the CATALIS FAST TRACK Evaluation Service was extremely positive, delivering a significant reduction in study approval timelines. We look forward to continuing this partnership and integrating the FAST TRACK evaluation into our processes to accelerate trial activation and bring innovative treatments to patients faster." - Dr. Daniel Martinez, Executive Medical Director, Amgen Canada Inc. | | | “At the MUHC, clinical trials have benefited numerous Quebec patients and have also contributed to changing practice globally. The faster clinical trials can be activated, the greater the opportunity for patients to benefit from these treatments. CATALIS facilitated the activation of this trial in 9.8 weeks, making our site the first to open in Canada. This is a tremendous achievement and provides the opportunity for people in our province to access a new and promising treatment.” - Benjamin Shieh MD, Associate Investigator, RI-MUHC, Assistant Professor, Department of Medicine, McGill University | | Two Clinical Trials on Asthma Conducted by Sanofi Are Authorized in a Record Median Time of
6.7 Weeks at the CHUS | Sanofi used CATALIS' for two Phase II studies, AIRCULES and AIRLYMPUS, focusing on asthma. The research team led by Dr. Simon Couillard of the Centre Hospitalier de l’Université de Sherbrooke (CHUS) obtained authorization for these two studies in record time: 6.8 weeks for the AIRCULES study and 6.6 weeks for the AIRLYMPUS study. | | | "Sanofi is proud to see the exceptional results achieved through the FAST TRACK Evaluation Service of CATALIS for our AIRCULES and AIRLYMPUS studies. With record authorization times of 6.8 and 6.6 weeks, respectively, this collaboration demonstrates the remarkable efficiency of the FAST TRACK evaluation process in Quebec. This strategic partnership not only accelerates the development of innovative treatments for asthma patients but also positions Quebec as a global leader in clinical asthma research." - Jean-François Léger, Site Partnership Manager, Clinical Research Unit, Sanofi Canada | | | "As a young clinical researcher, benefiting from the support and process of the CATALIS' FAST TRACK Evaluation Service for the AIRCULES and AIRLYMPUS studies allowed me to maximize recruitment opportunities for patients. The CATALIS team was professional and efficient, and I now approach every potential clinical study with the request that it be supported by CATALIS." - Simon Couillard-Castonguay MD, Professor, Faculté de médecine et des sciences de la santé (FMSS), Université de Sherbrooke | | CATALIS Is Organizing the First Clinical Trials Quebec Forum for Its Network | CATALIS Quebec, with the support of the Quebec government, is organizing the Clinical Trials Quebec Forum, a major event where we will have the great honor of welcoming Ms. Christine Fréchette, Minister of Economy, Innovation and Energy, and Mr. Christian Dubé, Minister of Health. Their presence underscores the Quebec government's commitment to clinical research and to health innovation. The aim of the Forum is to provide an update on the government's strategic vision while promoting exchanges, innovation, and the creation of synergies for the future of clinical research in Quebec. Together with leaders from health institutions and research centers, pharmaceutical companies, patient associations, patient partners, as well as decision-makers and representatives from government agencies, we aim to strengthen collective leadership in clinical research in Quebec, while aligning our efforts with the province's major objectives. This event aligns with our mission to ensure a high-performance clinical research environment in the province for the well-being and health of patients. | Survey for the Creation of the Future Directory of Biotechnology Providers in Quebec | CATALIS Quebec, in partnership with BIO Quebec, launched a survey to feed the future Directory of biotechnology providers in Quebec. This provincial tool, which will soon be available on the Clinical Trials Quebec website, will showcase Quebec’s expertise to sponsors wishing to carry out their clinical research in the province. Ensure your company's visibility in the Directory at launch by filling out the questionnaire today! | The CATALIS Team Is Growing | | | Lucyle Depoërs Science Communications Advisor Lucyle holds a PhD in molecular biology and is certified in project management with a focus on marketing. Passionate about scientific communication, she has combined her expertise in immuno-oncology research with initiatives aimed at making science accessible to the general public. She is now joining the team to promote Quebec's expertise in clinical research. | | | | Dali Haddad Project Lead
Dali has over 10 years of experience in the pharmaceutical industry. He has worked in regulatory affairs, sales, logistics, and pharmaceutical business development. Before joining CATALIS, he worked as a research coordinator at the MUHC, where he gained expertise in managing multicenter projects. As Project Lead, he will play a key role in the development of the FAST TRACK Evaluation Service. | | | | Ramiya Veluppillai Project Lead
Ramiya gained experience as a clinical coordinator at the Institute Specialized Medicine Intervention, then as a medical care coordinator at Mindspace by Numinus. She later worked as a research associate at the IR-CUSM, where she developed skills in managing multicenter projects. As Project Lead at CATALIS Quebec, she will contribute to the development of the FAST TRACK Evaluation Service. | | | CATALIS Quebec is a non-profit partnership dedicated to operational excellence in clinical research in Quebec, and since 2017, it has been carrying out a government mandate to optimize the clinical research environment in the province. Clinical Trials Quebec, powered by CATALIS Quebec, provides comprehensive and accessible information about clinical research and promotes access to clinical trials for Quebecers. | Discover Our Tools and Services: | Follow us on LinkedIn to learn why Quebec is a world leader in clinical trials. | | | | |
.png?1743712545421)
.png?1744295956177)
.png?1744062851684)
.png?1742571269792)
_(1).png?1743779391077)
.png?1738879138774)
_(1).png?1742823270236)
